Related Experiment Videos

Membrane cofactor protein (MCP; CD46). Isoforms differ in protection against the classical pathway of complement

M K Liszewski1, J P Atkinson

  • 1Division of Rheumatology, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.

Insights

Membrane cofactor protein (MCP; CD46) isoforms BC offer superior protection against complement activation via the classical pathway. These findings highlight the biological significance of MCP isoform variation and its therapeutic potential.

Area of Science:

  • Immunology
  • Molecular Biology

Background:

  • Membrane cofactor protein (MCP; CD46) is a key regulator of complement activation on host cells.
  • MCP exists as four main isoforms generated by alternative splicing, differing in O-glycosylation domains and cytoplasmic tails.

Purpose of the Study:

  • To characterize the complement inhibitory profiles of the four common MCP isoforms.
  • To determine the functional significance of isoform-specific differences in O-glycosylation and cytoplasmic tails.

Main Methods:

  • Comparison of C4b binding affinities across MCP isoforms.
  • Cytoprotection assays using transfected isoforms with equivalent copy numbers.
  • Assessment of C4b cleavage efficiency by individual MCP isoforms.

Main Results:

  • MCP isoforms (BC) with larger O-glycosylation domains exhibited higher C4b binding efficiency compared to smaller, less glycosylated C isoforms.
  • BC isoforms provided enhanced cytoprotection in classical pathway-mediated complement activation.
  • BC isoforms demonstrated more efficient cleavage of cell-bound C4b than C isoforms.

Conclusions:

  • MCP BC isoforms preferentially inhibit the classical pathway of complement activation.
  • Isoform variation in MCP plays a significant physiological role in complement regulation.
  • MCP isoforms hold therapeutic potential as complement inhibitors, particularly in xenotransplantation.

Related Concept Videos